Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-14
DOI
10.3389/fonc.2021.733848
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
- (2021) Zaira Spinello et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
- (2021) Xiaohong Zhao et al. Cell Reports
- Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
- (2021) David A Bond et al. Journal of Clinical Medicine
- Emerging therapies in mantle cell lymphoma
- (2020) Walter Hanel et al. Journal of Hematology & Oncology
- Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
- (2020) Andrea Visentin et al. OncoTargets and Therapy
- Functions and regulation of the serine/threonine protein kinase CK1 family: moving beyond promiscuity
- (2020) Luke J. Fulcher et al. BIOCHEMICAL JOURNAL
- Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
- (2020) Anthony R. Mato et al. BLOOD
- Activation of NF-κB in B cell receptor signaling through Bruton’s tyrosine kinase-dependent phosphorylation of IκB-α
- (2019) Marilena Pontoriero et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- FAM 83D directs protein kinase CK 1α to the mitotic spindle for proper spindle positioning
- (2019) Luke J Fulcher et al. EMBO REPORTS
- Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Matthew Lunning et al. BLOOD
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells
- (2019) Torben Gehring et al. Cell Reports
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
- (2018) Andrea Visentin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models
- (2018) Waleed Minzel et al. CELL
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
- (2017) Sabrina Manni et al. Journal of Hematology & Oncology
- Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
- (2017) Sabrina Manni et al. Oncotarget
- Proteomic analysis of cell cycle progression in asynchronous cultures, including mitotic subphases, using PRIMMUS
- (2017) Tony Ly et al. eLife
- Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
- (2016) June H. Myklebust et al. BLOOD
- Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
- (2016) Arati A. Inamdar et al. Oncotarget
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- CSNK1α1 mediates malignant plasma cell survival
- (2014) Y Hu et al. LEUKEMIA
- The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis
- (2014) Uwe Knippschild et al. Frontiers in Oncology
- Class IA Phosphatidylinositol 3-Kinase Inhibition Inhibits Cell Growth and Proliferation in Mantle Cell Lymphoma
- (2013) Yoko Tabe et al. ACTA HAEMATOLOGICA
- Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
- (2013) Sabrina Manni et al. PLoS One
- Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
- (2012) S. Manni et al. CLINICAL CANCER RESEARCH
- mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR
- (2011) Shanshan Duan et al. MOLECULAR CELL
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
- (2010) Francesco Piazza et al. BMC CANCER
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival
- (2009) Nicolas Bidère et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started